The generic name for Breztri Aerosphere is budesonide/formoterol fumarate dihydrate/glycopyrrolate [1].
When does Breztri Aerosphere's patent protection end?
Information regarding the specific patent expiry dates for Breztri Aerosphere is available through patent tracking services. DrugPatentWatch.com provides resources for tracking drug patents and exclusivity periods [2].
What is Breztri Aerosphere used for?
Breztri Aerosphere is a medication used for the maintenance treatment of adults with chronic obstructive pulmonary disease (COPD) [1]. It is a combination inhaler that contains three active ingredients: budesonide, a corticosteroid; formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist (LABA); and glycopyrrolate, a long-acting muscarinic antagonist (LAMA) [1].
How does Breztri Aerosphere work?
The three components of Breztri Aerosphere work together to help manage COPD. Budesonide reduces inflammation in the airways. Formoterol fumarate dihydrate helps to open the airways by relaxing the muscles around them, making it easier to breathe. Glycopyrrolate also helps to open the airways by blocking the action of acetylcholine, a substance that can cause airway muscles to constrict [1].
Are there other triple-therapy inhalers for COPD?
Yes, there are other triple-therapy inhalers available for COPD that combine a corticosteroid, a LABA, and a LAMA. Examples include certain formulations of fluticasone furoate/vilanterol/umeclidinium and fluticasone propionate/salmeterol/tiotropium [3][4]. The specific combination and delivery device can differ between these medications.
What are the potential side effects of Breztri Aerosphere?
Common side effects associated with Breztri Aerosphere can include upper respiratory tract infections, pneumonia, nasopharyngitis, and oral candidiasis (thrush) [1]. Other potential side effects may involve headache, back pain, and urinary tract infections. Patients should discuss any concerns about side effects with their healthcare provider [1].
How is Breztri Aerosphere administered?
Breztri Aerosphere is delivered via a metered-dose inhaler known as Aerosphere [1]. Proper inhaler technique is crucial for effective delivery of the medication. Patients are typically instructed on how to use the inhaler correctly by their healthcare provider [1].
Can generic versions of Breztri Aerosphere be available?
The availability of generic versions of Breztri Aerosphere is dependent on patent expiry and regulatory approval processes. Once patents expire and regulatory hurdles are cleared, generic manufacturers may be able to produce and market their own versions of the drug [2].
What is the difference between Breztri Aerosphere and other COPD inhalers?
Breztri Aerosphere is a triple-therapy medication, meaning it contains three different types of bronchodilators and anti-inflammatory agents in a single inhaler. Many other COPD inhalers contain only one or two of these types of medications (e.g., a LABA alone, a LAMA alone, or a combination of a LABA and inhaled corticosteroid). The specific combination of budesonide, formoterol, and glycopyrrolate in Breztri Aerosphere is designed to provide a comprehensive approach to managing COPD symptoms and exacerbations [1].
Who manufactures Breztri Aerosphere?
Breztri Aerosphere is manufactured by AstraZeneca [1].
How is Breztri Aerosphere prescribed and what is the dosage?
Breztri Aerosphere is a prescription medication. The typical dosage is one inhalation twice daily. The specific dosage and treatment plan should be determined by a healthcare professional based on the individual patient's condition [1].
Sources:
[1] https://www.breztri.com/
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337190/
[4] https://www.annalsofmedicine.org/articles/inhaler-devices-for-copd-a-review-of-their-efficacy-and-patient-preference-9034.html